218
Views
13
CrossRef citations to date
0
Altmetric
Review

Advances in the management of glioblastoma: the role of temozolomide and MGMT testing

, &
Pages 1-9 | Published online: 27 Dec 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Niklas Thon, Simone Kreth & Friedrich-Wilhelm Kreth. (2013) Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. OncoTargets and Therapy 6, pages 1363-1372.
Read now
Helge Frieling & André Tadić. (2013) Value of genetic and epigenetic testing as biomarkers of response to antidepressant treatment. International Review of Psychiatry 25:5, pages 572-578.
Read now

Articles from other publishers (11)

G. P. Guens, V. D. Sanikovich, V. A. Mileyko & A. A. Lebedeva. (2021) Glioblastoma: a molecular genetic portrait and modern therapeutic strategies for drug treatment. Advances in Molecular Oncology 8:3, pages 60-76.
Crossref
Tatyana Alexandrovna Bogoyavlenskaya, Ekaterina Evgenyevna Tyagunova, Roman Konstantinovich Kostin, Alexander Sergeevich Zaharov, Yuriy Leonidovich Vasil'ev & Olesya Vasilevna Kytko. (2021) Glioblastoma Break-in; Try Something New. International Journal of Cancer Management 14:1.
Crossref
Parth Thakkar, Brian Greenwald & Palak Patel. (2020) Rehabilitation of Adult Patients with Primary Brain Tumors: A Narrative Review. Brain Sciences 10:8, pages 492.
Crossref
Marianna A. Zolotovskaia, Maxim I. Sorokin, Ivan V. Petrov, Elena V. Poddubskaya, Alexey A. Moiseev, Marina I. Sekacheva, Nicolas M. Borisov, Victor S. Tkachev, Andrew V. Garazha, Andrey D. Kaprin, Peter V. Shegay, Alf Giese, Ella Kim, Sergey A. Roumiantsev & Anton A. Buzdin. (2020) Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology. International Journal of Molecular Sciences 21:5, pages 1580.
Crossref
Ali Saberinasab, Heidar Raissi & Hassan Hashemzadeh. (2019) Understanding the effect of vitamin B6 and PEG functionalization on improving the performance of carbon nanotubes in temozolomide anticancer drug transportation. Journal of Physics D: Applied Physics 52:39, pages 395402.
Crossref
Zimmer, Kim, Sprang, Leukel, Khafaji, Ringel, Sommer, Tuettenberg & Tuettenberg. (2019) GARP as an Immune Regulatory Molecule in the Tumor Microenvironment of Glioblastoma Multiforme. International Journal of Molecular Sciences 20:15, pages 3676.
Crossref
Riley L. Svec, Lucia Furiassi, Christine G. Skibinski, Timothy M. Fan, Gregory J. Riggins & Paul J. Hergenrother. (2018) Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma. ACS Chemical Biology 13:11, pages 3206-3216.
Crossref
Shang-Pen Huang, Yu-Chan Chang, Qie Hua Low, Alexander T.H. Wu, Chi-Long Chen, Yuan-Feng Lin & Michael Hsiao. (2017) BICD1 expression, as a potential biomarker for prognosis and predicting response to therapy in patients with glioblastomas . Oncotarget 8:69, pages 113766-113791.
Crossref
Enshan Feng, Changbai Sui, Tongxin Wang & Gaoling Sun. (2017) Temozolomide with or without Radiotherapy in Patients with Newly Diagnosed Glioblastoma Multiforme: A Meta-Analysis. European Neurology 77:3-4, pages 201-210.
Crossref
N. V. Lobanova, L. V. Shishkina, M. V. Ryzhova, G. L. Kobyakov, R. V. Sycheva, S. A. Burov, A. V. Lukyanov & Zh. R. Omarova. (2016) Clinical, immunohistochemical, and molecular genetic prognostic factors in adult patients with glioblastoma. Arkhiv patologii 78:4, pages 10.
Crossref
Ye. L. Choinzonov, O. V. Gribova, Zh. A. Startseva, A. I. Ryabova, V. A. Novikov, L. I. Musabayeva & I. S. Polezhayeva. (2014) CURRENT APPROACHES TO CHEMORADIOTHERAPY FOR MALIGNANT GLIOMAS. Bulletin of Siberian Medicine 13:3, pages 119-125.
Crossref